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Abstract
Background:  Alterations in arginine vasopressin regulation and secretion have been proposed as
one possible biochemical abnormality in patients with obsessive-compulsive disorder. In golden
hamsters, arginine vasopressin microinjections into the anterior hypothalamus trigger robust
grooming and flank marking, a stereotyped scent marking behaviors. The intensity and repetition
of the behaviors induced by arginine vasopressin is somewhat reminiscent of Obsessive Compulsive
Disorder in humans. The present experiments were carried out to test whether pharmacological
agents used to alleviate obsessive compulsive disorder could inhibit arginine vasopressin-induced
flank marking and grooming.
Results:  Male golden hamsters were treated daily for two weeks with either vehicle, fluoxetine,
clomipramine, or desipramine (an ineffective drug), before being tested for arginine vasopressin-
induced flank marking and grooming. Flank marking was significantly inhibited in animals treated
with fluoxetine or clomipramine but unaffected by treatment with desipramine. Grooming behavior
was not affected by any treatment.
Conclusion:  These data suggest that arginine vasopressin-induced flank marking may serve as an
animal model for screening drugs used in the control of Obsessive Compulsive Disorder.
Background
In golden hamsters, microinjections of arginine vaso-
pressin (AVP) into the anterior hypothalamus trigger
grooming and flank marking, a stereotyped scent mark-
ing behavior [1,2]. Within a minute after AVP microin-
jections, hamsters start to lick and comb sebaceous
glands situated on their dorsolateral flanks. Bouts of
flank gland grooming may be so intense that the flanks
are left matted and soaked in saliva. Flank marking be-
havior is observed soon after the onset of grooming, and
usually within two minutes of the microinjection. Flank
marking is a scent marking behavior involved in olfacto-
ry communication [3], and is characterized by arching
the back and rubbing the flank glands vigorously against
objects in the environment. The concentrations of AVP
required to induce flank marking are low (ranging from
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0.1 to 100 µM) [4,5] and the volumes microinjected in
the anterior hypothalamus are small (ranging from 20 to
100 nl). The activation of flank marking is dose-depend-
ent, and specific to AVP, as microinjections of other neu-
ropeptides, excitatory amino acids, and catecholamines
do not elicit the behavior [1,2,6]. Flank marking is also
specific to AVP V1 receptors, as the behavior is selectively
inhibited by V 1 receptor antagonists and activated by V1
receptor agonists [4,5].
The behavioral effects of AVP are not limited to flank
marking in hamsters. Vasopressin is a neurotransmitter
released centrally to affect various behaviors, e.g. arousal
[7], temperature regulation [8,9], aggression [10,11],
memory [12] and grooming [13]. However, the ability of
centrally acting AVP to induce intense stereotyped be-
haviors [1,14] raises the possibility that this neuropep-
tide may be associated with the induction of compulsive
behaviors in humans. Indeed, alterations in AVP regula-
tion and secretion are thought to be one possible bio-
chemical abnormality in patients with Obsessive
Compulsive Disorder (OCD) [15–18]. This disorder is
characterized by sudden, recurrent thoughts or images
that intrude into consciousness (obsessions) driving
stereotyped acts that the person feels compelled to per-
form (compulsions) [19]. Interestingly, patients with
OCD show elevated basal levels of AVP in the cerebrospi-
nal fluid and exaggerated plasma levels of AVP in re-
sponse to hypertonic challenge [16]. Many patients with
anorexia nervosa and bulimia nervosa, both compulsive
eating disorders, have abnormal levels of AVP in the cer-
ebrospinal fluid and plasma [15,17]. Pediatric patients
with severe OCD have low levels of AVP in cerebrospinal
fluid, while a subgroup of pediatric patients with com-
pulsive checking rituals has elevated AVP levels [18].
Hence, there are many clinical examples of compulsive
behavior associated with a perturbation in the AVP sys-
tem.
Given the association between AVP and OCD and the
stereotyped nature of AVP-induced flank gland groom-
ing and flank marking, the present studies were under-
taken to determine whether clomipramine and
fluoxetine, two drugs used to treat OCD in humans [20]
might inhibit these AVP-induced behaviors. Clomi-
pramine is a non-selective re-uptake inhibitor of serot-
onin, and to some extent norepinephrine [21] and
fluoxetine is a selective serotonin re-uptake inhibitor
[22]. Both of these drugs have proven to be effective in
different animals models of OCD [23]. As an additional
control, hamsters were also treated with desipramine, a
noradrenergic re-uptake inhibitor [24] that has been
found ineffective in inhibiting OCD in preclinical [25]
and clinical studies [26,27].
Results
Microinjection of 10 µM AVP caused robust grooming
and flank marking. In fact, animals groomed for up to
50% of the duration of the tests. The comparisons be-
tween groups showed some effects of treatment on flank
marking activity (F(3,25) = 3.6, p < 0.05) (Fig. 1). Animals
treated with clomipramine or fluoxetine flank marked
significantly less than vehicle-treated animals (p < 0.05).
Animals treated with desipramine flank marked as much
as vehicle-treated animals (p > 0.1), but flank marked
more than animals treated with clomipramine (p <
0.05). However, the comparisons failed to show any ef-
fect of treatment on grooming activity (F(3,25) = 0.61, p >
0.1) (Fig. 1). Indeed, regardless of treatment groups, the
animals spent a similar amount of time grooming after
microinjection of AVP.
Clomipramine caused a significant (F(2,15) = 124 p <
0.001) dose-dependent reduction in flank marking in-
duced by microinjection of 1.0 µM AVP (Fig 2). Flank
gland grooming was unaffected by drug treatments
(F(2,15) = .009 p > 0.9)
Discussion
In the present experiments, AVP-induced grooming and
flank marking behaviors were tested in hamsters ex-
posed to chronic treatment with psychotropic drugs
shown in preclinical and clinical studies to be effective in
the treatment of OCD [20,28]. The results show differen-
tial responsiveness to these treatments. While grooming
remained unaffected, flank marking was inhibited by
treatment with fluoxetine and clomipramine but not
Figure 1
Flank marking and grooming behavior (Mean ± SEM) follow-
ing microinjection of arginine vasopressin (10 µM in 100 nl
saline) in the anterior hypothalamus of golden hamsters
treated with vehicle (Veh), clomipramine (Clom),
desipramine (Des), and fluoxetine (Fluox). All animals were
treated with 2 mg/day for 2 weeks.
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desipramine. Clomipramine showed a dose-dependent
decrease in flank marking. These observations lead to
two main conclusions. The first conclusion is related to
the neurochemical properties of fluoxetine and clomi-
pramine. As noted earlier, fluoxetine is a selective serot-
onin re-uptake inhibitor while clomipramine is a non-
selective re-uptake inhibitor of serotonin, and to some
extent norepinephrine. The effectiveness of these drugs
presupposes a serotonin mechanism is involved in the
suppression of AVP-induced flank marking. The second
conclusion is related to observations on grooming. While
bouts of grooming are coincident with flank marking, the
selective inhibition of flank marking and not grooming
by clomipramine and fluoxetine suggest the two behav-
iors employ different neuronal networks and neuro-
chemical signals for their control. Although earlier
studies have implicated grooming behavior as a phenom-
enological correspondent to OCD [25,29] inhibited by
drugs like clomipramine or fluoxetine, the situation ap-
pears different for AVP-induced grooming in hamsters.
In canine acral lick dermatitis, the excessive licking of
the paws and flanks was significantly reduced by fluoxe-
tine and clomipramine two and three weeks into treat-
ment, respectively [25]. However, the scale of the
reduction was more pronounced over a five-week period
of treatment [25]. Perhaps flank gland grooming would
have been significantly altered in these studies if drug
treatment had been extended for several more weeks.
The present data show that AVP-induced flank marking
is selectively inhibited by chronic treatment with serot-
onin re-uptake inhibitors such as fluoxetine or clomi-
pramine, instead of noradrenergic re-uptake inhibitors
such as desipramine. Similar patterns of results have
been observed in animal models of OCD such as canine
acral lick [25]. These observations are not limited to an-
imal models. Selective serotonin re-uptake inhibitors are
recognized as an effective biological treatment for OCD
[20]. In a double blind, placebo control study, treating
over 500 patients with OCD, clomipramine was found to
be superior to placebo [30]. Differences between clomi-
pramine and placebo were noted as early as one week af-
ter the start of treatment, with significant clinical
improvement occurring after six weeks of treatment.
Fluoxetine also results in a significant reduction in OCD
severity that takes several weeks to realize [31,32]. This
therapeutic delay has been related to a down-regulation
of serotonin autoreceptors with chronic exposure to ele-
vated serotonin [33,34]. Together, these data have been
used to link OCD with a dysfunction in serotonin neuro-
transmission [35]. Of course, it is unclear whether pro-
longed treatment with these re-uptake inhibitors is
restricted to serotonin alone or impact on the activity of
other neurotransmitter systems. For example, chronic
treatment with fluoxetine decreases the release of AVP
from rat hypothalamic organ cultures [36]. This finding
is particularly noteworthy since alterations in AVP levels
in the cerebrospinal fluid have been correlated with oc-
currences of OCD [15,16]. The occurrence of OCD has
also been correlated with increased levels of oxytocin, a
neuropeptide closely related to AVP [37]. In golden ham-
sters, the elevation of serotonin in the anterior hypotha-
lamus following fluoxetine treatment can inhibit the
activity of the AVP system related to aggressive behavior
[10,11]. The ability of microinjected AVP in the anterior
hypothalamus to enhance aggressive behavior in golden
hamsters is blocked by fluoxetine treatment and seroton-
in 5HT1A receptor agonists [10]. The present data in-
clude AVP-stimulated flank marking in the list of
behaviors suppressed by fluoxetine treatment.
Conclusion
These results show AVP-induced flank marking is inhib-
ited by chronic treatment with fluoxetine or clomi-
pramine, but not desipramine. This pattern of
responsiveness to drug treatment suggests that AVP-in-
duced flank marking may be used as a model for screen-
ing psychotropics used in the treatment of OCD. It is a
cost-efficient, ethical alternative to existing models, and
can be useful in further advancing our understanding of
Figure 2
Clomipramine treatment results in a dose-dependent inhibi-
tion of flank marking behavioral following two weeks of clo-
mipramine treatment. Flank marking was triggered by the
microinjection of 1.0 µM AVP in the anterior hypothalamus.
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OCD. Future studies could focus on effects of long-term
elevation of AVP in hamsters; dose-response manipula-
tions of psychotropics or clinical use of AVP receptor an-
tagonists on humans to further investigate the role of
AVP in OCD.
Materials and methods
Animals and Treatment
Experiments were performed on adult male golden ham-
sters (Mesocricetus auratus) weighing approximately
160 g. The animals underwent stereotaxic surgery, and
were allowed to recover before behavioral testing. The
hamsters were kept on a reverse light cycle (14L: 10D,
lights on at 19:00) in Plexiglas cages, and received food
and water ad libitum. All behavioral tests were per-
formed during the dark phase of the circadian cycle un-
der dim red illumination. All animals were acquired and
cared for in accordance with the guidelines published in
the NIH Guide for the Care and Use of Laboratory Ani-
mals.
Animals were divided into four treatment groups: vehi-
cle control (Veh, 75% Tris-buffer saline, pH 7.4, and 25%
dimethyl sulfoxide; n=9), clomipramine hydrochloride
(Clom, 2 mg/day; n=8), desipramine hydrochloride
(Des, 2 mg/day; n=9) or fluoxetine hydrochloride
(Fluox, 2 mg/day, n=8). Animals were given subcutane-
ous injections each morning for two consecutive weeks.
The doses and treatment regimen for each drug were
comparable to those used in several preclinical studies
examining the pharmacological control of OCD
[25,38,39]. Acute drug trials were not attempted as the
experimental design followed that of previously pub-
lished studies [25,38,39]. After 2 weeks of treatment,
hamsters were tested for flank marking after a microin-
jection of AVP (10 µM in 100 nl saline). This dose results
in a maximal activation of flank marking [5]. Vaso-
pressin was microinjected into the anterior hypothala-
mus of the hamsters with a 1 µl Hamilton syringe
connected through PE-20 tubing to a 33-ga needle which
was inserted in the guide cannula and lowered to the tar-
get site. Vasopressin-triggered flank marking occurs
with 60 sec of microinjection and lasts for ca. 4–5 min
[5]. A trained observer recorded the number of flank
marks and the amount of time spent grooming for a 10-
minute period. All behaviors were videotaped for further
verification. Flank marking tests were run ca. 60–90 min
after subcutaneous drug treatments. The results were
compared between groups with ANOVAs followed by
Fisher PLSD post-hoc tests.
Although the effects of fluoxetine and clomipramine on
flank marking were statistically significant in the drug
comparison studies (Fig 1), the effects were limited to a
30–40% reduction. As noted, the microinjection of 10
µM AVP causes maximal flank marking, hence it is likely
the inhibition of behavior with drug treatment might
have been more pronounced if the animals were chal-
lenged with lower doses of AVP. To this end, dose-re-
sponse data for clomipramine were generated in animals
microinjected with 1.0 µM AVP. Three groups of six ani-
mals each were treated with vehicle, 0.001 mg/kg or
0.03 mg/kg of clomipramine each day for two consecu-
tive weeks. Since the initial drug trials were effective with
fluoxetine and clomipramine given in a dose of 2 mg/
day, this dose-response study worked in a range of 100–
10,000 times less clomipramine used in the initial trial.
On the day of testing, animals were treated with clomi-
pramine and 60–90 min later microinjected with 1.0 µM
AVP in a volume of 100 nl and scored for flank marking
and flank gland grooming.
Stereotaxic Surgery/Histology
Stereotaxic surgery was performed under pentobarbital
(Nembutal, 35 mg/kg, Abbott Laboratories, North Chi-
cago, I<) anaesthesia. The Stereotaxic coordinates were:
1.1 mm anterior to the bregma, 1.8 mm lateral to the mid-
sagittal suture at an 8° angle from the vertical line, and
4.5 mm below the dura. A unilateral 26-gauge guide can-
nula was lowered to the site and secured to the skull with
dental cement. The guide cannula was closed with a 33-
ga obturator extending 1 mm beyond the guide. The in-
ner-cannula used for microinjections extended 3.0 mm
beyond the guide to reach the anterior hypothalamus. At
the end of the study, animals were sacrificed by decapita-
tion, and their brains were taken out and fixed in 10%
formalin. Later, the brains were sliced on a vibratome
and the sections were stained with thionin to confirm the
location of the microinjection sites in the anterior hy-
pothalamus.
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